This statistic depicts the share of insulin glargine sales attributable to Lantus compared to its biosimilar from 2015 to 2017. In 2015, Lantus held 100 percent of the insulin glargine sales in the United States. However, as of November 2017, Lantus held 81.1 percent of the market while biosimilar Basaglar held 18.9 percent of the market.
Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Association for Accessible Medicines, & IQVIA. (February 13, 2018). Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017 [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Association for Accessible Medicines, und IQVIA. "Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017." Chart. February 13, 2018. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Association for Accessible Medicines, IQVIA. (2018). Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Association for Accessible Medicines, and IQVIA. "Insulin Glargine Market Share of Lantus and Its U.S. Biosimilar Competitor from 2015 to 2017." Statista, Statista Inc., 13 Feb 2018, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
Association for Accessible Medicines & IQVIA, Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017 Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/ (last visited November 10, 2024)
Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017 [Graph], Association for Accessible Medicines, & IQVIA, February 13, 2018. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/869905/percentage-lantus-sales-share-compared-to-biosimilar/
